Provided By GlobeNewswire
Last update: Mar 19, 2025
-Durable, Clinically Significant Improvements in Swallowing Function Achieved 12-months Post-Treatment with BB-301 for Subject 1-
-Durable, Clinically Significant Improvements in Swallowing Function Achieved 12-months Post-Treatment with BB-301 for Subject 2, with Subject 2 Achieving a Clinically Normal Swallowing Profile Following the Significant Reduction in Total Dysphagic Symptom Burden-
Read more at globenewswire.comNASDAQ:BNTC (7/31/2025, 2:33:22 PM)
11.17
-0.08 (-0.71%)
Find more stocks in the Stock Screener